University of Birmingham Panel Session

University of Birmingham Panel Session 

My name is Alice and I am a Research Scientist at Future Genetics.

In keeping with the ethos of empowerment at Future Genetics, Dr Mohammed Kamran, who is the CEO and Medical Director of the organisation, will be participating in a panel discussion being held at the University of Birmingham, titled ‘Insights into Science: in and out of Labs’. The event is being held on Wednesday the 30th of January.

This provides an opportunity for students at the University of Birmingham to gain insights into the career opportunities that are available to them and capture the experiences and perspectives of the panel speakers. The speaker panel consists of 6 members, that include 2 patent attorney and trademark specialists, an application team manager, a business engagement manager, a life sciences recruitment consultant, as well as Dr Kamran, who will provide insights into his academic, clinical trials and research and development experiences.

This event compliments another event that Dr Kamran spoke at, which was the Aston University Careers Event in December 2018. For those who are interested, please click the link below.

https://www.youtube.com/watch?v=_mR3DzL_qB4

Given our relationship with the University of Birmingham, we hope Future Genetics can add value to the next generation of Scientists, Entrepreneurs and Innovators. 

Thank You

Mental Health statistics: time to help

Mental illnesses are continuously affecting individuals and families. There are a wide range of mental illnesses that fall into different sub categories. Examples of mental illnesses include Depression, anxiety, Bipolar and Schizophrenia.

25% of young women suffer from a mental illness

Everyday more and more people are diagnosed with a mental illness especially women. Mental illnesses are also becoming more frequent in the younger population. A recent study conducted in 2017 by the NHS and involved more than 9,000 individuals. The results of this study were that 1 in 4 Young women will develop a mental illness and a total of 23.9% reported having a disorder.

More needs to be done around the topic of mental illnesses due to how common they are amongst the whole population. Mental illnesses are most common in young females. I believe that more needs to be done around the topic of mental illnesses due to how common they are amongst the whole population. As they are most common in young females I hope I will be able to help other young females who are suffering from a mental illness by contributing to creating awareness around this issue.

Poor Mental Health and triggers

There are many factors which may contribute to the development of a mental Illness in young females such as exam stress, which a large proportion of teenagers will have to face. Body image is also a significant factor. This factor is enhanced by social media which constantly promotes an idealistic image, in addition social media also causes a constant comparison against other girls. However, it is debatable whether or not social media can be solely blamed despite being a factor. Social media is extremely time consuming with nearly one third of children spending at least four hours on these apps. Those who did have a mental health problem were two to three times less likely to spend at least 4 hours on social media which shows it does have a negative impact. The ways it appears to have negative impact is by the number of likes, comparison and cyber-bullying as well. Despite this social media cannot be blamed as the only culprit. As sometimes social media can be used to support an individual who is suffering from a mental illness.

Affected populations & support frameworks

These factors are not only specific to females but males as well, especially the younger population, as 1 in 9 children aged between 5-15 are reported to have a disorder. This figure has been rising over the years as it now stands at 11.2% in comparison to 9.7% in 1999. Figures are constantly rising but not all young people are receiving the help and support they need. This is shown by how nearly a third of young individuals who were referred to community services got turned away. Even those who received help had to wait an alarming average time period of 2 months. 32% were waiting for treatment at the end of the year and 15% had to wait over 6 weeks to even be seen. This needs to change, young, at risk and vulnerable children should not have to wait these time periods to receive treatment or to be seen. 

Management of Arthritis using Biosimilar Molecules – an NHS perspective

Arthritis

Arthritis is an illness which affects numerous people and it results in the inflammation of the joints. It can affect one or multiple joints. There are several different forms of arthritis. Approximately 350 million people have Arthritis worldwide, with a total of 10 million of these people are living in the United Kingdom. This illness is treated by the use of a number of different drugs including a drug called Adalimumab. A protein called tumour necrosis factor (TNF) is produced by the immune system naturally. However, in arthritis, the inflammation is caused by a protein called tumour necrosis factor (TNF) being overproduced.

 

Adalimumab 

Adalimumab is a monoclonal antibody that acts as a TNF blocker. It it works by binding to the TNF molecules. The action of binding then prevents the molecules of TNF attaching to the body’s healthy cells. This then reduces inflammation of the joints.

 

My name is Lucy Field and I am a research Scientist at Future Genetics. I have just read an article that focuses on the development of a new drug which treats Arthritis.

 

Biosimilars

The new drug is a biosimilar version of Adalimumab. The development of this new drug has a positives impact on the NHS and their budget. The reasoning for this is because Adalimumab was a medicine that Hospitals spend nearly £400 million a year on making it a relatively expensive medicine. The new biosimilar version will only cost a quarter of this amount allowing the NHS to save up to £300 million a year by 2021. This outstanding cut from the national annual medicines bill is the biggest NHS saving from a single drug negotiation.

 

NHS Cost Savings

The money from this saving could be used to employ 11,700 more community nurses or 19,800 more breast cancer treatments for patients which could potentially save the lives of thousands of women. This highlights the importance of biosimilar drugs and how a smarter approach to biosimilar drugs across Europe gives patients and taxpayers a better deal.

The saving is due to negotiations with 5 new drug companies who will manufacture bio-similar versions of the dug. These companies are Amgen, Biogen, Mylan/Fujifilm Kyowa Kirin, Sandoz, and AbbVie. This comes after the exclusive patent for Adalimumab (Humira) expired. From December onwards, the new biosimilar versions of the drug from these new companies should be available.

According to the NHS 9 out of 10 new patients should be started on the best value medicine 3 months after the launch of the biosimilar medicine.

Women and Neurological Diseases

Women and Neurological Diseases

Overview

Neurological diseases are among the leading causes of mortality and disabilities in the elderly population. Parkinsonism, strokes and Dementia come under the umbrella term of Neurological diseases. These neurological diseases have a detrimental effect on not only the patient but their family and caregivers. They are also known to show substantial co-occurrence, therefore an individual with Dementia has an increased risk of stroke.

The study 

My name is Lucy Field and I am research Scientist at Future Genetics. I have recently read an article which was published by University medical centre in Rotterdam which focuses on Neurological diseases. They conducted a study; the objective of this study was to ‘quantify the burden of common neurological disease in older adults in terms of lifetime risks such as co-occurrence and preventive potential. In this study the health of 12,102 people was monitored over a 26-year period in the years 1990 to 2016. The long duration of the study allows clear identification of co-occurrence of a disease and allows a large sample size giving more reliable data and conclusions

Study conclusion 

The  overall conclusion of this research study was that one in two women and one in three men will develop a Neurological disease in their lifetime. This shows it is more common in women than men, throughout the study data on women was compared with men. The study mainly focuses on age, as all of the individuals involved were above the age of 45. There was evidence to show women are more likely to develop a neurological disease. Not only as a female but a female scientist I believe it is important to raise awareness. Through this article I hope to educate more women about the risk of these common disease allowing us to further educate more women.

 Study Findings

In the study Dementia was seen to be the most common disease with a total of 1489 individual’s being diagnosed, then 1,285 suffered from a stroke. Ischemic strokes were more common at 64.7% and 9.8% had a hemorrhagic stroke. Parkinsonism was the least common neurological disease with 263 individuals’ being diagnosed. A lot of individual’s are only diagnosed with one of the diseases in their lifespan. However, at the age of 45 there was a substantial risk of being diagnosed with multiple diseases. A total of 438 individuals were diagnosed with multiple diseases. Following the trend of more women being affected by one neurological disease, more women were diagnosed with multiple diseases a total of 4% Versus 3% of men. Women were also almost twice as likely to be diagnosed with both stroke and dementia. These high figures show the importance of the need for better prevention strategies.

Neurological disease versus Other common diseases

Neurological diseases get under investigated in comparison to common diseases such as cancer and heart disease. This is because Cancer and Heart disease commonly affect middle aged individual and and neurological diseases normally have a later onset. According to this study, this should not be the case as the lifetime risk of developing Breast cancer in 1 in 8 compared to 1 in 2 developing a neurological disease. The same principle applies for heart disease which affects 1 in 4 people. Those who had been diagnosed with one of the neurological diseases had a higher prevalence of high blood pressure, type 2 diabetes and an abnormal heart rhythm.

Importance of Preventative interventions

These findings clearly display the importance of preventative interventions which will delay the onset. It has been estimated that if the onset of the diseases is delayed by 1 to 3 years, the remaining risk of developing would be reduced by 20% in 45-year olds and 50% in those older than 85. This huge reduction in both age categories, this demonstrates the importance of the development of a treatment to delay the onset and to maintain a healthy brain. This is one of Future genetics aims.

Licher SDarweesh SKLWolters FJ, et al
Lifetime risk of common neurological diseases in the elderly population

Future Genetics will be at the Lab Innovations Conference

Future Genetics will be at the Lab Innovations Conference, 2018

 

Future Genetics is committed to high quality and innovative genomics research.

Our Research Scientist, Lucy Field, will be attending the Lab Innovations 2018 Conference at the NEC this week (31 Oct). She looks forward to meeting you all and learning from all the exciting exhibitions which will be showcased.

 

Future Genetics will be looking for new and innovative technologies that can help us accelerate our research in genomics, medicine and patient healthcare.

Looking forward to the conference